Cassava sciences completes patient dosing in a randomized controlled trial of simufilam in alzheimer's disease

Austin, texas, may 11, 2023 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a clinical-stage biotechnology company, today announced the completion of patient dosing in a 6-month, randomized controlled trial of simufilam in over 125 patients with alzheimer's disease. this trial is known as the cognition maintenance study (cms). simufilam is cassava sciences' investigational oral drug treatment for alzheimer's disease dementia.
SAVA Ratings Summary
SAVA Quant Ranking